C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
PF-08653944PF-08653944PF-08653944PF-08653944Placebo to match PF-08653944
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Body weight percent change from baseline (CFB) at Week 72.
Endpoint detail
Body weight (kg) CFB at Week 72., Waist circumference (cm) CFB at Week 72., SBP (mmHg) CFB at Week 72., IWQoL-Lite-CT Physical Function composite score CFB at Week 72.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.